Latest Operating Expenses News

Mayfield Childcare Limited reported a 5% revenue increase and a 14% rise in underlying EBITDA for Q3 FY25, alongside a $2.4 million debt reduction and an extended borrowing facility. The company also ended a planned divestment and announced a new community partnership.

Stakk Limited reports a staggering 1,836% year-on-year increase in quarterly receipts, positioning itself on track to hit an $8 million annual recurring revenue target by mid-2026.

Australian Pacific Coal’s Dartbrook Mine has entered voluntary administration and receivership, with the company’s interest now considered to hold no value amid mounting secured debt pressures. Despite this, the company remains solvent with limited cash reserves and continues to assess its next steps.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Omni Bridgeway reported a strong start to FY26 with A$136.6 million in cash investment proceeds and a robust pipeline of nearly A$318 million in potential new commitments. The company also settled a long-standing legal liability and is progressing well with fund capital raising.

Austral Gold’s Q3 report reveals a sharp production drop at Guanaco following a fatal accident, prompting a downward revision of 2025 output and cost hikes, while Casposo’s refurbishment signals a new growth phase.

WhiteHawk Limited reports steady Q3 revenue and advances key contracts, positioning itself to capitalise on new U.S. cybersecurity compliance rules.

Brookside Energy reported solid production growth and financial gains in Q3 2025, driven by the Bruins well's full-quarter output and a strategic new area of interest in the Anadarko Basin. The company also initiated a share buy-back and advanced plans for a US listing.

Sovereign Metals advances its Kasiya Rutile-Graphite Project with strategic infrastructure funding from Japan, key feasibility study completions, and strong graphite test results amid shifting global supply dynamics.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

EZZ Life Science Holdings reported a 25% drop in Q1 receipts, driven by seasonal softness and campaign timing, while accelerating its US market entry and launching three new health supplements.

Aeris Environmental Ltd reports strong Q1 FY26 growth, expanding its Syncromesh smart building platform into new sectors and international markets while maintaining solid financial discipline.